Overview Quality Outlook Risk & rank Results Accounts Options Guidance & governance
Guidance tracker
What DRREDDY guided, and what came next
| Filed | What the filing says | Next results: profit YoY | Revenue | Move on the day |
|---|---|---|---|---|
| 28 Jul 2026 | Dr. Reddy's filed the transcript of its Q1 FY27 earnings call held on July 22, 2026, for the quarter ended June 30, 2026, uploaded to its website. Consolidated revenue was ₹8,071 crores (US$853 million), down 5.6% YoY and up 7.4% sequentially, per CFO M. V. Narasimham; the decline was mainly lower lenalidomide... NSE copy | -31.3 % | -1.5 % | +6.6 % |
| 15 Jul 2026 | Dr. Reddy's filed the transcript of its July 9, 2026 conference call on the semaglutide update, which the company held after a disclosure made earlier that day. Management (CEO Erez Israeli) said an impurity was found out of specification in finished drug product made from a scale-up batch of semaglutide API; the... NSE copy | -68.7 % | -5.5 % | -1.4 % |
| 30 Oct 2025 | Dr. Reddy's filed the transcript of its Q2FY26 earnings call held on October 24, 2025, for the quarter and half-year ended September 30, 2025, and uploaded it to its website. Management (CFO M. V. Narasimham) said consolidated revenue was ₹8,805 crores ($992 million), up 9.8% year-over-year, with EBITDA margin at... NSE copy | -14.4 % | +4.4 % | +5.2 % |
| 29 Jul 2025 | Dr. Reddy's filed the transcript of its Q1FY26 earnings call held on July 23, 2025, with the link to the transcript on its website. Management said consolidated revenue was ₹8,545 crores (US$997 million), up 11% YoY and flat QoQ; EBITDA margin was 26.7%; PAT was ₹1,419 crores, up 2% YoY and down 11% QoQ. Management... NSE copy | +7.3 % | +9.8 % | +0.1 % |
| 15 May 2025 | Dr. Reddy's filed the transcript of its Q4 and FY25 earnings call held on May 9, 2025, with a link to the transcript on its website. Management (CEO Erez Israeli, CFO M. V. Narasimham) said Q4FY25 consolidated revenue was ₹8,506 crores (up 20% YoY) and FY25 revenue was ₹32,554 crores (up 17%), including the... NSE copy | +1.8 % | +11.4 % | +1.5 % |
| 29 Jan 2025 | Dr. Reddy's filed the transcript of its Q3FY25 earnings call held on January 23, 2025, for the quarter ended December 31, 2024, uploaded to its website. Management said consolidated revenue was Rs. 8,359 crores (US$977 million), up 16% YoY and 4% QoQ, including Rs. 605 crores from the acquired NRT business;... NSE copy | +21.6 % | +19.9 % | +3.4 % |
| 11 Nov 2024 | Dr. Reddy's filed the transcript of its Q2 FY25 earnings call held on November 5, 2024, for the quarter and half-year ended September 30, 2024. Management (CEO Erez Israeli, CFO MV Narasimham) said consolidated revenue was Rs. 8,016 crores, up 17% YoY and 4% QoQ, with reported EBITDA margin of 28.4% and underlying... NSE copy | +2.4 % | +15.8 % | -5.0 % |
| 01 Aug 2024 | Dr. Reddy's filed the transcript of its Q1FY25 earnings call held on July 27, 2024, under Regulation 30, and posted it on its website. Management reported consolidated revenue of Rs. 7,673 crores, up 14% YoY, and EBITDA of Rs. 2,160 crores with a 28.2% margin; PAT was Rs. 1,392 crores. Management guided SG&A at... NSE copy | -15.3 % | +16.5 % | +2.4 % |
| 02 Jul 2024 | Dr. Reddy's filed the transcript of its investor call held on June 26, 2024, on the acquisition of Nicotinell and related brands outside the US from Haleon plc. Erez Israeli (CEO) said the portfolio had revenues of GBP 217 million in 2023, is margin-accretive, and the total consideration is GBP 500 million (GBP 458... NSE copy | -0.9 % | +13.9 % | -0.6 % |
| 13 May 2024 | Dr. Reddy's filed the transcript of its Q4 and FY24 earnings call held on May 7, 2024, uploaded to its website. Management (CFO Parag Agarwal) said Q4 FY24 consolidated revenue was Rs. 7,083 crores ($850 million), up 12% YoY and down 2% QoQ; FY24 revenue was Rs. 27,916 crores ($3.35 billion), up 14%. Management... NSE copy | -0.9 % | +13.9 % | -0.6 % |
| 05 Feb 2024 | Dr. Reddy's filed the transcript of its Q3FY24 earnings call held on January 30, 2024, for the quarter and nine months ended December 31, 2023. Management (CEO Erez Israeli, CFO Parag Agarwal) reported consolidated revenue of Rs. 7,215 crores ($867 million), up 7% YoY, with EBITDA of Rs. 2,111 crores and a 29.3%... NSE copy | +36.4 % | +12.6 % | -3.2 % |
| 01 Nov 2023 | Dr. Reddy's filed the transcript of its Q2 FY24 earnings call held on October 27, 2023, for the quarter and half year ended September 30, 2023. Parag Agarwal (CFO) said consolidated revenue was Rs. 6,880 crores (US$ 828 million), up 9% year-on-year and 2% sequentially, with EBITDA of Rs. 2,181 crores (31.7% margin)... NSE copy | +11.0 % | +6.6 % | +4.8 % |
Filings tagged as guidance, newest first (12 in all), with the company's next results after each: profit and revenue against the same quarter a year before, and the share's move on the results day. Whether the guidance was met is for the reader to judge from both; the site does not score it. The summaries are written by an AI model from the filing and can be wrong - the filing is the source.
Governance
Management, auditors, ratings and legal matters
| Filed | Kind | What the filing says |
|---|---|---|
| 23 Oct 2026 | Management change | Dr. Reddy's Laboratories reported unaudited consolidated IFRS results for Q2 FY27 and H1 FY27 (quarter and six months ended September 30, 2026), approved by the Board on October 23, 2026. Q2 FY27 revenues were Rs 86,708 Mn (down 1.5% YoY, up 7.4% QoQ), with gross margin of 52.1%, EBITDA of Rs 17,828 Mn (20.6% of... NSE copy |
| 23 Oct 2026 | Legal or regulatory | Dr. Reddy's Laboratories filed its investor presentation on unaudited consolidated (IFRS) financial results for the quarter and half year ended September 30, 2026 (Q2 FY27). Q2 FY27 reported revenue was ₹8,671 Cr, down 1.5% YoY and up 7% QoQ; the company said reported YoY decline reflected lower lenalidomide sales,... NSE copy |
| 28 Jul 2026 | Legal or regulatory | Dr. Reddy's filed the transcript of its Q1 FY27 earnings call held on July 22, 2026, for the quarter ended June 30, 2026, uploaded to its website. Consolidated revenue was ₹8,071 crores (US$853 million), down 5.6% YoY and up 7.4% sequentially, per CFO M. V. Narasimham; the decline was mainly lower lenalidomide... NSE copy |
| 22 Jul 2026 | Legal or regulatory, Management change | Dr. Reddy's board on July 22, 2026 approved unaudited consolidated IFRS and Indian GAAP results for the quarter ended June 30, 2026: revenue Rs 80,705 million (vs Rs 85,452 million a year earlier), profit for the period Rs 4,348 million (vs Rs 14,096 million), basic EPS Rs 5.32 (vs Rs 17.04). A provision of Rs... NSE copy |
| 15 Jul 2026 | Legal or regulatory | Dr. Reddy's filed the transcript of its July 9, 2026 conference call on the semaglutide update, which the company held after a disclosure made earlier that day. Management (CEO Erez Israeli) said an impurity was found out of specification in finished drug product made from a scale-up batch of semaglutide API; the... NSE copy |
| 12 May 2026 | Legal or regulatory, Management change | Board of Dr. Reddy's Laboratories approved audited results for the quarter and year ended March 31, 2026, with consolidated IFRS revenues of INR 335,933 million for FY2026 (INR 325,535 million in FY2025) and profit for the year of INR 42,466 million (INR 57,245 million in FY2025). For Q4 FY2026, consolidated IFRS... NSE copy |
| 21 Jan 2026 | Legal or regulatory | Board of Dr. Reddy's Laboratories approved unaudited financial results for the quarter and nine months ended December 31, 2025 at its meeting on January 21, 2026. Q3 FY26 consolidated revenue (IFRS) was Rs 87,268 million, against Rs 83,586 million in the year-ago quarter; quarterly profit attributable to equity... NSE copy |
| 30 Oct 2025 | Legal or regulatory | Dr. Reddy's filed the transcript of its Q2FY26 earnings call held on October 24, 2025, for the quarter and half-year ended September 30, 2025, and uploaded it to its website. Management (CFO M. V. Narasimham) said consolidated revenue was ₹8,805 crores ($992 million), up 9.8% year-over-year, with EBITDA margin at... NSE copy |
| 24 Oct 2025 | Legal or regulatory | Dr. Reddy's Laboratories' board approved unaudited financial results for the quarter and half-year ended September 30, 2025 at a meeting held October 24, 2025 (2:00 PM to 3:57 PM IST). Consolidated revenue for Q2 FY26 was Rs 88,051 million, up from Rs 80,162 million a year earlier; half-year revenue was Rs 173,503... NSE copy |
| 23 Jul 2025 | Legal or regulatory | Board of Dr. Reddy's Laboratories approved unaudited consolidated IFRS results for the quarter ended June 30, 2025 at a meeting held July 23, 2025 (2:15 p.m. to 3:43 p.m. IST). Consolidated revenue for Q1 FY26 was Rs 85,452 million, up from Rs 76,727 million a year earlier, and profit for the period was Rs 14,096... NSE copy |
| 09 May 2025 | Management change | Board of Dr. Reddy's Laboratories approved audited consolidated (IFRS and Indian GAAP) and standalone financial results for the quarter and year ended March 31, 2025, with statutory auditors issuing unmodified opinions. Board recommended a final dividend of Rs. 8 per equity share of Rs. 1 each for FY 2024-25;... NSE copy |
| 24 Jan 2025 | Legal or regulatory | Dr. Reddy's Laboratories filed its unaudited consolidated IFRS results for the quarter and nine months ended December 31, 2024 (integrated filing dated January 24, 2025; board approval January 23, 2025). Q3 FY25 revenue from operations was Rs 83,586 million, up from Rs 72,148 million a year earlier; profit for the... NSE copy |
| 23 Jan 2025 | Legal or regulatory | Dr. Reddy's Laboratories' board approved unaudited financial results for the quarter and nine months ended December 31, 2024 at a meeting held January 23, 2025. Consolidated revenue (IFRS) for Q3 FY25 was Rs 83,586 million, up from Rs 72,148 million a year earlier; profit for the period was Rs 14,038 million versus... NSE copy |
| 27 Dec 2024 | Credit rating | Dr. Reddy's Laboratories filed under Regulation 30 that ICRA Limited has reaffirmed/assigned credit ratings on the Company's bank facilities. Long-term fund-based/non-fund-based bank facilities of Rs. 2,000.00 crore rated [ICRA]AA+ (Stable), reaffirmed/assigned for enhanced amount. The annexure lists Rs. 1,995.00... NSE copy |
| 19 Nov 2024 | Credit rating | Dr. Reddy's filed under Regulation 30 to disclose bank facility rating actions by India Ratings & Research (Ind-Ra) dated 19 November 2024. Ind-Ra affirmed the long-term rating at IND AA+/Stable and short-term rating at IND A1+ on fund-based working capital limits of INR4,800 million (State Bank of India) and... NSE copy |
| 11 Nov 2024 | Legal or regulatory | Dr. Reddy's filed the transcript of its Q2 FY25 earnings call held on November 5, 2024, for the quarter and half-year ended September 30, 2024. Management (CEO Erez Israeli, CFO MV Narasimham) said consolidated revenue was Rs. 8,016 crores, up 17% YoY and 4% QoQ, with reported EBITDA margin of 28.4% and underlying... NSE copy |
| 01 Aug 2024 | Management change | Dr. Reddy's filed the transcript of its Q1FY25 earnings call held on July 27, 2024, under Regulation 30, and posted it on its website. Management reported consolidated revenue of Rs. 7,673 crores, up 14% YoY, and EBITDA of Rs. 2,160 crores with a 28.2% margin; PAT was Rs. 1,392 crores. Management guided SG&A at... NSE copy |
| 27 Jul 2024 | Management change | Board meeting outcome dated July 27, 2024: approved unaudited consolidated (IFRS and Ind AS) and standalone results for the quarter ended June 30, 2024. Board approved sub-division of each equity share of Rs.5 face value into 5 equity shares of Re.1 each, subject to member approval by postal ballot; record date to... NSE copy |
| 02 Jul 2024 | Legal or regulatory | Dr. Reddy's filed the transcript of its investor call held on June 26, 2024, on the acquisition of Nicotinell and related brands outside the US from Haleon plc. Erez Israeli (CEO) said the portfolio had revenues of GBP 217 million in 2023, is margin-accretive, and the total consideration is GBP 500 million (GBP 458... NSE copy |
| 05 Jun 2024 | Credit rating | Dr. Reddy's Laboratories filed a Regulation 30 disclosure that ICRA Limited has reaffirmed the [ICRA]AA+ (Stable) long-term rating on Rs. 500 crore bank facilities. ICRA also assigned [ICRA]AA+ (Stable) to Rs. 700 crore of enhanced bank facilities, taking the total rated bank facilities to Rs. 1,200 crore. The ICRA... NSE copy |
Filings with a management change, a legal or regulatory matter or a credit rating (by their tags), or naming an auditor, a resignation or a pledge of shares; newest first (31 in all). A list of what was filed, not a judgement of the company.